1상모집 중

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

연구 개요

The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).

스폰서
리드: 얀센(J&J)
적응증
Acute Lymphoblastic Leukemia, Acute Leukemias, Acute Myeloid Leukemia
중재
14C-bleximenib, bleximenib
목표 등록
10
시작일
2025-11-18
완료(예정)
2026-07-13

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.